Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)

BACKGROUND: Pemetrexed has shown a favourable response rate of about 30% with minimal toxicity when used as a single agent for treatment of advanced urothelial carcinoma. This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Y J, Lee, S H, Lee, J-L, Ahn, J-H, Lee, K-H, You, D, Hong, B, Hong, J H, Ahn, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453451/
https://www.ncbi.nlm.nih.gov/pubmed/25429526
http://dx.doi.org/10.1038/bjc.2014.591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453451/
https://www.ncbi.nlm.nih.gov/pubmed/25429526
http://dx.doi.org/10.1038/bjc.2014.591

Ejemplares similares